Marta Schilling brings over 30 years of experience in cell and gene therapies, specializing in cGMP manufacturing and development. Her career began at Baxter Healthcare (later Nexell Therapeutics), where she was involved in the research, development, and customer support of the Isolex® CD34 Cell Selection System and the CytoMate® Cell Washer Device. She supported customers across the United States, Canada, Europe, and Australia in developing their cell therapy programs. At IDM Pharma, Marta served as the Associate Director of the Cell Processing Laboratory, where she was instrumental in setting up the cGMP manufacturing facility and systems. She significantly contributed to process improvements for producing IDM’s autologous dendritic cell vaccines in Phase I/II clinical trials.

​

Marta's expertise continued to grow at Progenitor Cell Therapy, where she was the Senior Director of Manufacturing Operations/Technical Director, overseeing operations at the Mountain View, CA, Contract Development Manufacturing Organization (CDMO) focused exclusively on cell and gene therapies. As Vice President of Manufacturing at Prima BioMed, she oversaw Chemistry Manufacturing and Controls (CMC) and cGMP manufacturing for the lead clinical candidate, Cvac®, ensuring harmonization and comparability between manufacturing processes across the USA, Europe, and Australia. At ImmunoCellular Therapeutics (IMUC), Marta served as Vice President of Cell Therapy Manufacturing, overseeing CMC for their product pipeline, including a Phase III autologous dendritic cell therapy for treating newly diagnosed glioblastoma in North America and Europe.